Description: Biomm S.A. operates as a biotechnology company in Brazil. It offers AFREZZA, a human insulin inhalation powder; GHEMAXAN, an enoxaparina sodica; GLARGILIN, a glargine insulin; WOSULIN R, a human insulin; WOSULIN N, isphane insulin; HERZUMA, a trastuzumab; and CANETA LIFEPEN G PARA APLICACAO DE INSULINA. The company was founded in 2001 and is headquartered in Nova Lima, Brazil.
Home Page: www.biomm.com
Rua dos Pinheiros, 610
São Paulo,
SP
05422-001
Brazil
Phone:
55 11 3509 1700
Officers
| Name | Title |
|---|---|
| Mr. Heraldo Marchezini | CEO & Member of The Exec. Board |
| Ms. Mirna Santiago Vieira | CFO, Investor Relations Officer & Member of Exec. Board |
| Mr. Francisco Carlos Marques de Freitas | COO & Member of The Exec. Board |
| Mr. Francisco Rafael Costa Jr. | Commercial Director & Member of Exec. Board |
Exchange: SA
Country: BR
Currency: Brazilian real (R$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.629 |
| Price-to-Sales TTM: | 4.4007 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 148 |